Why Psychedelic Therapy Research Gets First US Government Funding in Decades?

The latest research into psilocybin therapy as a treatment for tobacco addiction has yielded promising results.

Johns Hopkins Medicine was awarded a US$4-million grant by the National Institutes of Health (NIH) to further clinical research investigating psilocybin-assisted psychotherapy to treat tobacco addiction. The grant is the first federal funding in half a century to be directed at clinical research on the therapeutic effects of a classical psychedelic.

The so-called psychedelic renaissance has been chugging away for around 20 years now and to date it has been mostly funded by non-profit organizations, wealthy philanthropists, and more recently for-profit companies trying to get a piece of the looming multi-billion dollar psychedelic medicine industry.

From MDMA for PTSD to psilocybin for depression, a number of promising new psychedelic therapies are on the precipice of clinical approval. Yet these substances are still classified as Schedule 1 drugs, considered to have no “accepted medical use and a high potential for abuse”.

The new grant, from the NIH’s National Institute on Drug Abuse, focuses on a three-year multisite clinical trial looking at how effectively psilocybin-assisted psychotherapy can help people quit smoking. Matthew Johnson, principle investigator on the project, has been investigating psilocybin as a tool for smoking cessation for well over a decade.

Entheogen-assisted Healing

Taking entheogens can be like air travel: people do it all the time, it’s usually fine, but when it’s not fine, it’s sometimes very bad. We’ve been there. And that’s where an experienced GUIDE can make the difference in the outcome.
I’m available by phone if you or someone you know wants to ask questions of ANY nature. Use this link to schedule a call HERE.